JLE

Hépato-Gastro & Oncologie Digestive

MENU

Towards integration of immune checkpoint inhibitors into clinical practice for advanced squamous cell oesophageal cancers Volume 30, supplement 4, September 2023

Figures


  • Figure 1

  • Figure 2

Tables

Authors
1 Institut régional du Cancer de Montpellier (ICM), Département d’oncologie médicale, 208 avenue des Apothicaires, 34000, Montpellier
2 Institut de Recherche sur le Cancer de Montpellier (IRCM), Inserm U-1194 (Equipe Immunité et Cancer), 124 avenue des Apothicaires, 34000 Montpellier
* Correspondance : A. Adenis

Several recent studies have shown that immunotherapy in combination with fluoropyrimidine/platinum chemotherapy or other immunotherapy can ­reduce the risk of death in patients with advanced oesophageal squamous cell ­carcinoma, as compared to standard treatment with chemotherapy plus placebo. A ­Marketing Authorisation has been granted by the European Medicines Agency for the use of nivolumab and ipilimumab (combined with nivolumab) in patients with tumours expressing PDL1 (TPS ≥ 1). Also, a Marketing Authorisation has been granted to pembrolizumab combined with chemotherapy in patients with PDL1-expressing tumours with a CPS ≥ 10. In France, only access to pembrolizumab or nivolumab is currently funded.